Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:18 PM
Ignite Modification Date:
2025-12-24 @ 9:18 PM
NCT ID:
NCT02810704
Eligibility Criteria:
Inclusion Criteria:
1. 21 years of age or older;
2. Undergoing elective primary, revision or second stage re-implantation total hip/knee replacement or uni-compartmental knee replacement or hip resurfacing arthroplasty;
3. Has necessary mental capacity to participate and is able to comply with study protocol requirements;
4. Eligible for randomization to at least two of the three study regimens;
5. Is not pregnant on the day of surgery;
6. Has signed the consent form; and
7. Is willing to be randomized and participate in the study.
Exclusion Criteria:
1. Undergoing bilateral hip or knee replacement;
2. Has been previously enrolled;
3. Is pregnant or breastfeeding;
4. Is on chronic anticoagulation other than antiplatelet medications;
5. Concurrently enrolled in another active interventional clinical trial testing a drug or intervention known or believed to interact with aspirin, warfarin, or rivaroxaban;
6. Has documented gastrointestinal, cerebral, or other hemorrhage within 3 months;
7. Has a known diagnosis of defective hemostasis and past history of clinical bleeding requiring transfusion and treatment;
8. Has had an operative procedure involving the eye, ear, or central nervous system within one month;
9. Has uncontrolled hypertension with systolic BP \> 220mmHg or diastolic BP \> 120mmHg;
10. Body weight of less than 41 kilograms at baseline visit;
11. Member of a vulnerable patient population.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
21 Years
Study:
NCT02810704
Study Brief:
Protocol Section:
NCT02810704